Table 1 Patient characteristics
From: Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
Group | Women/men (% women) | Age: years ± SD (range) | Mean EDSS at the sampling (interval) | Treatment duration (months or infusions ± SD) | Previous treatment |
|---|---|---|---|---|---|
HD (n = 23) | 18/5 (78 %) | 33 ± 11 (20–60) | n.d. | n.d. | n.d. |
UT (n = 19) | 12/7 (63 %) | 41 ± 8 (27–57) | 1.3 (0–3) | n.d. | n.d. |
GA (n = 26) | 16/10 (62 %) | 44 ± 11 (22–60) | 1.9 (0–8.5) | 45 ± 38 (1–122) | 13/26 IFNb; 9/26 nv; 4/26 IS |
IFNb (n = 26) | 15/11 (58 %) | 36 ± 11 (24–65) | 1.6 (0–5) | 51 ± 48 (3–147) | 25/26 nv; 1/26 GA |
NTZ (n = 113) | 76/37 (67 %) | 37 ± 9 (19–60) | 2.9 (0–8) | 35 ± 24 (1–86) | 52/113 IFNb; 23/113 GA; 13/113 IS; 12/113 nv; 6/113 FTY; 7/113 other treatments |
RTX (n = 18) | 15/3 (83 %) | 41 ± 10 (30–65) | 4.4 (2–7) | 1.25 (1–3) | 1/18 IFNb; 1/18 GA; 5/18 FTY; 9/18 NTZ; 2/18 n.d. |
FTY (n = 23) | 15/8 (65 %) | 41 ± 9 (21–57) | 3.1 (0–6.5) | 15 ± 8 (1–29) | 1/23 nv; 8/23 NTZ; 5/23 GA; 5/23 IFNb; 2/23 IS; 2/23 other treatments |